Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 151 to 200 of 295

TitleTypeExpected publication date
Molnupiravir for treating COVID 19 [ID6340]Technology appraisal guidance
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]Technology appraisal guidanceTBC
Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221Technology appraisal guidanceTBC
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]Technology appraisal guidanceTBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Technology appraisal guidanceTBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Technology appraisal guidanceTBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidance
NY-ESO-1 T-cells for treating synovial sarcoma ID1286Technology appraisal guidanceTBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Technology appraisal guidanceTBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]Technology appraisal guidanceTBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Technology appraisal guidance
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]Technology appraisal guidanceTBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
ONS-5010 for treating wet age-related macular degeneration ID6320Technology appraisal guidanceTBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
OrganOx metra for liver transplant [ID5116]Technology appraisal guidanceTBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Technology appraisal guidance
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Technology appraisal guidanceTBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]Technology appraisal guidanceTBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Technology appraisal guidanceTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Palopegteriparatide for treating chronic hypoparathyroidism ID6380Technology appraisal guidanceTBC
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]Technology appraisal guidanceTBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594Technology appraisal guidanceTBC
Pegcetacoplan for treating geographic atrophy [ID4041]Technology appraisal guidanceTBC
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]Technology appraisal guidance
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Technology appraisal guidanceTBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332Technology appraisal guidanceTBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]Technology appraisal guidanceTBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All